CA3233625A1 - Imidazopyridazine il-17 inhibitor compounds - Google Patents

Imidazopyridazine il-17 inhibitor compounds Download PDF

Info

Publication number
CA3233625A1
CA3233625A1 CA3233625A CA3233625A CA3233625A1 CA 3233625 A1 CA3233625 A1 CA 3233625A1 CA 3233625 A CA3233625 A CA 3233625A CA 3233625 A CA3233625 A CA 3233625A CA 3233625 A1 CA3233625 A1 CA 3233625A1
Authority
CA
Canada
Prior art keywords
alkyl
cycloalkyl
substituted
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3233625A
Other languages
English (en)
French (fr)
Inventor
Steven D. Goldberg
Deane GORDON
Steven A. LOSKOT
Stefan MCCARVER
Steven P. Meduna
Brock T. Shireman
Alexander E. VALDES
Dongpei Wu
Xiaohua XUE
Luke E. HANNA
Jennifer D. Venable
Douglas C. Behenna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA3233625A1 publication Critical patent/CA3233625A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3233625A 2021-09-27 2022-09-26 Imidazopyridazine il-17 inhibitor compounds Pending CA3233625A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163248563P 2021-09-27 2021-09-27
US63/248,563 2021-09-27
US202163273407P 2021-10-29 2021-10-29
US63/273,407 2021-10-29
US202263371910P 2022-08-19 2022-08-19
US63/371,910 2022-08-19
PCT/US2022/077000 WO2023049886A1 (en) 2021-09-27 2022-09-26 Imidazopyridazine il-17 inhibitor compounds

Publications (1)

Publication Number Publication Date
CA3233625A1 true CA3233625A1 (en) 2023-03-30

Family

ID=83693127

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3233625A Pending CA3233625A1 (en) 2021-09-27 2022-09-26 Imidazopyridazine il-17 inhibitor compounds

Country Status (10)

Country Link
US (2) US12215111B2 (https=)
EP (1) EP4408529A1 (https=)
JP (1) JP2024536863A (https=)
KR (1) KR20240082371A (https=)
AU (1) AU2022348938A1 (https=)
CA (1) CA3233625A1 (https=)
MX (1) MX2024003770A (https=)
TW (1) TW202329933A (https=)
UY (1) UY39957A (https=)
WO (1) WO2023049886A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240082371A (ko) 2021-09-27 2024-06-10 얀센 파마슈티카 엔브이 이미다조피리다진 il-17 억제제 화합물
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
WO2024138286A1 (en) * 2022-12-26 2024-07-04 Usynova Pharmaceuticals, Ltd. Il-17a modulators
WO2024163365A1 (en) * 2023-01-30 2024-08-08 Dice Alpha, Inc. Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof
CN121311483A (zh) * 2023-03-28 2026-01-09 詹森药业有限公司 含内酰胺的咪唑并哒嗪il-17抑制剂化合物
WO2025202922A1 (en) * 2024-03-27 2025-10-02 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752400B (zh) * 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
GB201909190D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
KR20230019507A (ko) 2020-04-30 2023-02-08 얀센 파마슈티카 엔.브이. Il-17의 조절제로서의 이미다조피리다진
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
KR20240082371A (ko) 2021-09-27 2024-06-10 얀센 파마슈티카 엔브이 이미다조피리다진 il-17 억제제 화합물
CN116143777A (zh) 2021-11-04 2023-05-23 四川海思科制药有限公司 一种可抑制il-17a的杂环化合物及其用途
TW202413363A (zh) 2021-11-04 2024-04-01 大陸商西藏海思科製藥有限公司 一種可抑制il-17a之雜環化合物及其用途

Also Published As

Publication number Publication date
US12215111B2 (en) 2025-02-04
MX2024003770A (es) 2024-06-19
US20230147458A1 (en) 2023-05-11
UY39957A (es) 2023-04-14
EP4408529A1 (en) 2024-08-07
WO2023049886A1 (en) 2023-03-30
AU2022348938A1 (en) 2024-05-16
TW202329933A (zh) 2023-08-01
US20250206744A1 (en) 2025-06-26
JP2024536863A (ja) 2024-10-08
KR20240082371A (ko) 2024-06-10

Similar Documents

Publication Publication Date Title
CA3233625A1 (en) Imidazopyridazine il-17 inhibitor compounds
JP6688352B2 (ja) 補体媒介障害の治療のためのアリール化合物、ヘテロアリール化合物及び複素環式化合物
KR102849047B1 (ko) 피롤로피리미딘 itk 억제제
ES2881395T3 (es) Composiciones y métodos para inhibir la actividad de la arginasa
RU2684324C1 (ru) Бициклические конденсированные гетероарильные или арильные соединения в качестве модуляторов IRAK4
AU2017201536B2 (en) Pyrimidinyl Tyrosine Kinase Inhibitors
CA3181676A1 (en) Imidazopyridazines as modulators of il-17
CA3233408A1 (en) Imidazopyridazine il-17 inhibitor compounds
CA3233622A1 (en) Benzimidazole and azabenzimidazole il-17 inhibitor compounds
CA3181793A1 (en) Imidazopyrimidines as modulators of il-17
WO2021022178A1 (en) Substituted sulfonamide pyrrolopyridines as jak inhibitors
TW202540125A (zh) 雙環雜芳基化合物
WO2025202931A1 (en) Imidazopyridazine il-17 inhibitor compounds
CN118076606A (zh) 咪唑并哒嗪il-17抑制剂化合物
HK1209284B (zh) 嘧啶基酪氨酸激酶抑制劑
HK1254323B (zh) 作为irak4调节剂的双环稠合杂芳基或芳基化合物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240806

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240806

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250805

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250805